Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.
NCT04912011
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
COVID-19 Pneumonia
Interventions
DRUG:
Canrenoate Potassium
DRUG:
Normal Saline
Sponsor
Pomeranian Medical University Szczecin